- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06264726
CommunityRx-malattia cardiovascolare (CRx-CVD)
CommunityRx-malattie cardiovascolari: implementazione di HealtheRx per ridurre le disuguaglianze sanitarie nelle zone rurali della Carolina del Nord orientale
The goal of this single arm pre-test post-test design study is to test the impact of providing patients with information about community-based resources to address health-related social needs and cardiometabolic health in rural African American patients. The main question it aims to answer is:
• What is the effectiveness of community resource information on patient self-efficacy to use community resources?
Participants will be given:
- A personalized "HealtheRx" resource with information about community resources related to food, housing, utility support, transportation, and crisis support. The HealtheRx is personalized for patients based on their age and zip code.
- Access to a community resource navigator for support with using the HealtheRx upon request
- 2 text messages with reminders about the HealtheRx and access to the community resource navigator
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Rocky Mount, North Carolina, Stati Uniti, 27801
- OIC Family Medical Center - Fairview
-
Rocky Mount, North Carolina, Stati Uniti, 27804
- OIC Family Medical Center - Happy Hill
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
patient
-
African American
-
age 2 or older
-
Have at least one cardiometabolic condition:
- Overweight (BMI greater than or equal to 25 kg/m^2);
- Obesity (BMI greater than or equal to 30 kg/m^2);
- ICD-9 or 10 diagnostic code for overweight or obesity
- Adult prehypertension (SBP 120 to 129 and DBP greater than 80 mmHg);
- Adult hypertension (SBP greater than or equal to130 or DBP = 80 mmHg);
- Pediatric Prehypertension (SBP or DBP greater than or equal to 90th but <95th percentile)
- Pediatric Hypertension (SBP or DBP greater than or equal to 95th percentile);
- ICD-9 or 10 diagnostic code for hypertension
- Adult and Pediatric Prediabetes (Fasting glucose 100-125 mg/dL or OGTT 140-199 mg/dL)
- Adult and Pediatric Diabetes (FPG greater than or equal to126 mg/dL (7.0 mmol/L) or OGTT greater than or equal to 200 mg/dL (11.1mmol/L) or HgbA1C greater than or equal to 6.5);
- ICD-9 or 10 diagnostic code for diabetes, pre-diabetes or elevated glucose, or gestational diabetes;
- Adult and Pediatric Total cholesterol (>200mg/dL; LDL >130mg/dL; HDL < 35 mg/dL; TG greater than or equal to150mg/dL);
- ICD-9 or 10 diagnostic code for hyperlipidemia
Exclusion Criteria:
- Unable to read, speak or understand English
- Unable to receive text message or email communications
- Living in the same household as someone already enrolled in the CRx-CVD study
- Adults with limited life expectancy (e.g., advanced cancer, end stage liver disease, hospice)
- Adults receiving treatment for cancer
- Adults living in skilled nursing facilities
- Dementia/other significant cognitive impairment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intervention Group
This group will receive the intervention |
CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Participant Self-efficacy for Finding Community Resources
Lasso di tempo: Baseline, up to 6 months
|
Change in self-efficacy for finding community resources is measured using one item constructed from Bandura's Self-Efficacy Scale which asks, "How confident are you in your ability to find resources in your community that help you manage your health?" Responses will be assessed on a 5-point Likert scale ranging from 1= "not at all confident" to 5= "completely confident." Lower scores indicate lower levels of confidence, and higher scores indicate higher levels of confidence. |
Baseline, up to 6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Participant Knowledge of Community Resources
Lasso di tempo: Baseline, up to 6 months
|
Change in participant knowledge of community resources is measured using 10 self-reported survey items adapted and tested in prior CommunityRx studies asking, "For each place that I list, please tell me if you know of places like this in your community: [insert community resource]." The change in the mean number of "yes" responses will be reported. |
Baseline, up to 6 months
|
|
Change in Participant Utilization of Community Resources
Lasso di tempo: Baseline, up to 6 months
|
Change in participant utilization of community resources is measured using 10 self-reported survey items adapted and tested in prior CommunityRx studies asking participants "Have you received services from places like this for you or your household in the last 6 months?" The change in the mean number of "yes" responses will be reported. |
Baseline, up to 6 months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Gaurav Dave, MBBS, DrPH, Unviersity of North Carolina at Chapel Hill
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 23-0254
- R01HL150909 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Periodo di condivisione IPD
Beginning 9 and continuing for 36 months following publication
Criteri di accesso alla condivisione IPD
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .